Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments
Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering
EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization
Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics
Regulatory News:
